文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

PET引导的骨髓保护放疗用于局部晚期宫颈癌:INTERTECC II/III期最终结果

Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-08-20

国际II/III期试验纳入101例IB-IVA期宫颈癌患者,比较PET引导骨髓保护IG-IMRT与标准IG-IMRT同步顺铂后装治疗。III期因无效提前关闭;PET-BMS-IMRT显著降低急性≥3级中性粒细胞减少,但未影响顺铂周期数、PFS、OS或失败模式,治疗相关淋巴细胞减少无差异。

要点

  • PET-BMS-IMRT较标准IMRT显著降低急性≥3级中性粒细胞减少(合并队列13% vs 35%)。
  • 两组顺铂周期数、PFS、OS及失败模式无差异,III期因无效提前关闭。
  • 治疗前后绝对淋巴细胞计数无组间差异,预处理ALC与OS关联证据弱。

核心结论

  • PET-BMS-IMRT显著降低急性≥3级中性粒细胞减少,但未降低治疗相关淋巴细胞减少。
  • 无证据表明PET-BMS-IMRT影响化疗实施或长期结局,预处理ALC与OS关联证据弱。

研究设计与样本

  • 国际II/III期试验,纳入101例IB-IVA期宫颈癌患者,II期非随机分配,III期随机分配。
  • III期主要终点为无进展生存(PFS),因无效提前关闭,入组29例(PET-BMS-IMRT组16例,IMRT组13例)。

主要发现

  • 全组5年PFS为73.6%(95%CI 64.9%-84.3%),5年OS为84%(95%CI 76%-92.9%)。
  • 随机患者中急性≥3级中性粒细胞减少PET-BMS-IMRT组19% vs IMRT组54%(χ2P=.048),合并队列13% vs 35%(χ2P=.01)。
  • 预处理ALC≤1.5 k/µL者 multivariable分析OS较差但无统计学意义(HR 2.85;95%CI 0.94-8.62;校正P=.216)。
  • 两组顺铂周期数、OS、PFS及失败模式无差异,治疗后ALC无组间差异。

临床怎么用

  • 对局部晚期宫颈癌同步放化疗患者,PET-BMS-IMRT可减少急性≥3级中性粒细胞减少。
  • 骨髓保护策略未显示影响化疗实施或长期生存,临床可考虑用于降低血液学毒性。

局限性

  • III期因无效提前关闭,随机样本量小(29例),长期结局比较效能不足。
  • 预处理ALC与OS关联为事后探索性分析,证据弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To test effects of positron emission tomography (PET)-based bone marrow-sparing (BMS) image-guided intensity modulated radiation therapy (IG-IMRT) on efficacy and toxicity for patients with locoregionally advanced cervical cancer. METHODS AND MATERIALS: In an international phase II/III trial, patients with stage IB-IVA cervical carcinoma were treated with either PET-based BMS-IG-IMRT (PET-BMS-IMRT group) or standard image-guided IMRT (IMRT group), with concurrent cisplatin (40 mg/m2 weekly), followed by brachytherapy. The phase II component nonrandomly assigned patients to PET-BMS-IMRT or standard IMRT. The phase III trial randomized patients to PET-BMS-IMRT versus IMRT, with a primary endpoint of progression-free survival (PFS) but was closed early for futility. Phase III patients were analyzed separately and in combination with phase II patients, comparing acute hematologic toxicity, cisplatin delivery, PFS, overall survival (OS), and patterns of failure. In a post-hoc exploratory analysis, we investigated the association between pretreatment absolute lymphocyte count (ALC) and OS. RESULTS: In total, 101 patients were enrolled on the phase II/III trial, including 29 enrolled in phase III (PET-BMS-IMRT group: 16; IMRT group: 13) before early closure. Median follow-up was 33 months for phase III patients and 39 months for all patients. PFS and OS at 5 years for all patients were 73.6% (95% confidence interval [CI], 64.9%-84.3%) and 84% (95% CI, 76%-92.9%]), respectively. There were no differences in number of cisplatin cycles, OS, PFS, or patterns of failure between groups for the combined cohort. The incidence of acute grade ≥ 3 neutropenia was significantly lower in the PET-BMS-IMRT group compared with IMRT for randomized patients (19% vs 54%, χ2P = .048) and in the combined cohort (13% vs 35%, χ2P = .01). Patients with pretreatment ALC ≤ 1.5 k/µL had nonsignificantly worse OS on multivariable analysis (HR 2.85; 95% CI, 0.94-8.62; adjusted P = .216), compared with patients with ALC > 1.5 k/µL. There was no difference in posttreatment ALC by treatment group. CONCLUSIONS: PET-BMS-IMRT significantly reduced acute grade ≥3 neutropenia, but not treatment-related lymphopenia, compared with standard IMRT. We found no evidence that PET-BMS-IMRT affected chemotherapy delivery or long-term outcomes, and weak evidence of an association between pretreatment ALC and OS.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Williamson CW, Sirák I, Xu R, et al. Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial. Int J Radiat Oncol Biol Phys. 2021. PMID: 34419564. doi:10.1016/j.ijrobp.2021.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。